Inhaled steroids with and without regular formoterol for asthma: serious adverse events

Abstract

Inhaled steroids with and without regular formoterol for asthma: serious adverse events (Review)

Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials

“…This conclusion is also in agreement with findings from recent cumulative reviews of ICS/LABA vs. ICS trials in asthma focused on specific LABA products formoterol [26] and salmeterol [27], where overall mortality rate in the ICS/LABA arms was not significantly different from the rate in the ICS arms, and was equal to 1 death per 1000 patients treated for 26 weeks (i.e., 2 deaths per 1000 patient-years, with the same estimate for ICS/formoterol and ICS/salmeterol products).…”

Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials

“…This conclusion is also in agreement with findings from recent cumulative reviews of ICS/LABA vs. ICS trials in asthma focused on specific LABA products formoterol [26] and salmeterol [27], where overall mortality rate in the ICS/LABA arms was not significantly different from the rate in the ICS arms, and was equal to 1 death per 1000 patients treated for 26 weeks (i.e., 2 deaths per 1000 patient-years, with the same estimate for ICS/formoterol and ICS/salmeterol products).…”

Retrospective Analysis of the Starting Dose of Combined ICS/LABA for Cough-variant Asthma and Cough-predominant Asthma

“…Notably, we found that it seems to be important to improve symptoms using bronchodilators as well as antiinflammatory treatment at an early stage. Indeed, mediumdose ICS/LABA can significantly improve early morning peak flow as well as airway hypersensitivity, and it is comparable to ICSs alone in terms of safety (19)(20)(21)(22)(23).…”

Adoption and implementation of maintenance and reliever therapy for adults with moderate-to-severe asthma

“… 21 Notably, no difference in risk of death or non-fatal serious adverse events have been found to date in patents taking combined ICS-formoterol versus ICS alone. 22 …”

Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials

“…This conclusion is also in agreement with findings from recent cumulative reviews of ICS/LABA vs. ICS trials in asthma focused on specific LABA products formoterol [26] and salmeterol [27], where overall mortality rate in the ICS/LABA arms was not significantly different from the rate in the ICS arms, and was equal to 1 death per 1000 patients treated for 26 weeks (i.e., 2 deaths per 1000 patient-years, with the same estimate for ICS/formoterol and ICS/salmeterol products).…”

Retrospective Analysis of the Starting Dose of Combined ICS/LABA for Cough-variant Asthma and Cough-predominant Asthma

“…Notably, we found that it seems to be important to improve symptoms using bronchodilators as well as antiinflammatory treatment at an early stage. Indeed, mediumdose ICS/LABA can significantly improve early morning peak flow as well as airway hypersensitivity, and it is comparable to ICSs alone in terms of safety (19)(20)(21)(22)(23).…”

Adoption and implementation of maintenance and reliever therapy for adults with moderate-to-severe asthma

“… 21 Notably, no difference in risk of death or non-fatal serious adverse events have been found to date in patents taking combined ICS-formoterol versus ICS alone. 22 …”

Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials

“…This conclusion is also in agreement with findings from recent cumulative reviews of ICS/LABA vs. ICS trials in asthma focused on specific LABA products formoterol [26] and salmeterol [27], where overall mortality rate in the ICS/LABA arms was not significantly different from the rate in the ICS arms, and was equal to 1 death per 1000 patients treated for 26 weeks (i.e., 2 deaths per 1000 patient-years, with the same estimate for ICS/formoterol and ICS/salmeterol products).…”

Retrospective Analysis of the Starting Dose of Combined ICS/LABA for Cough-variant Asthma and Cough-predominant Asthma

“…Notably, we found that it seems to be important to improve symptoms using bronchodilators as well as antiinflammatory treatment at an early stage. Indeed, mediumdose ICS/LABA can significantly improve early morning peak flow as well as airway hypersensitivity, and it is comparable to ICSs alone in terms of safety (19)(20)(21)(22)(23).…”

Adoption and implementation of maintenance and reliever therapy for adults with moderate-to-severe asthma

“… 21 Notably, no difference in risk of death or non-fatal serious adverse events have been found to date in patents taking combined ICS-formoterol versus ICS alone. 22 …”